Zentalis Pharmaceuticals (NASDAQ:ZNTL) Research Coverage Started at Mizuho

Posted by Francis Steltz on Jul 20th, 2026

Mizuho started coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note issued to investors on Friday morning, Marketbeat reports. The firm issued an outperform rating and a $8.00 price target on the stock.

Other research analysts also recently issued research reports about the company. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Guggenheim raised their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $6.14.

Get Our Latest Stock Analysis on ZNTL

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $5.11 on Friday. The firm has a fifty day moving average of $4.10 and a two-hundred day moving average of $3.36. Zentalis Pharmaceuticals has a 12-month low of $1.21 and a 12-month high of $6.95. The firm has a market capitalization of $363.78 million, a P/E ratio of -2.95 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). Equities research analysts expect that Zentalis Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. increased its holdings in shares of Zentalis Pharmaceuticals by 31.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 723,075 shares of the company’s stock valued at $1,092,000 after acquiring an additional 172,628 shares during the last quarter. Anfield Capital Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 239.9% in the 4th quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock valued at $328,000 after acquiring an additional 171,228 shares in the last quarter. 5AM Venture Management LLC lifted its holdings in Zentalis Pharmaceuticals by 705.7% in the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock worth $5,330,000 after purchasing an additional 3,457,913 shares during the last quarter. Ishara Investments LP acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter worth approximately $1,782,000. Finally, CTC Alternative Strategies Ltd. acquired a new stake in Zentalis Pharmaceuticals in the 1st quarter worth approximately $29,000.

Zentalis Pharmaceuticals Company Profile

(Get Free Report)

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.